B
Barbara Leutgeb
Researcher at Solvay
Publications - 4
Citations - 589
Barbara Leutgeb is an academic researcher from Solvay. The author has contributed to research in topics: Pharmacokinetics & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 498 citations. Previous affiliations of Barbara Leutgeb include Heidelberg University.
Papers
More filters
Journal ArticleDOI
G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension.
Angela Wirth,Zoltán Benyó,Zoltán Benyó,Martina Lukasova,Barbara Leutgeb,Barbara Leutgeb,Nina Wettschureck,Stefan Gorbey,Petra Örsy,Béla Horváth,Christiane Maser-Gluth,Erich Greiner,Erich Greiner,Björn Lemmer,Günther Schütz,J. Silvio Gutkind,Stefan Offermanns +16 more
TL;DR: It is shown that Gq-G11-mediated signaling in smooth muscle cells is required for maintenance of basal blood pressure and for the development of salt-induced hypertension, which identifies the G12-G13–LARG–mediated signaling pathway as a new target for antihypertensive therapies that would be expected to leave normal blood pressure regulation unaffected.
Journal ArticleDOI
Corrigendum: G12-G13|[ndash]|LARG|[ndash]|mediated signaling in vascular smooth muscle is required for salt-induced hypertension
Angela Wirth,Zoltán Benyó,Martina Lukasova,Barbara Leutgeb,Nina Wettschureck,Stefan Gorbey,Petra Örsy,Béla Horváth,Christiane Maser-Gluth,Erich Greiner,Björn Lemmer,Günther Schütz,J. Silvio Gutkind,Stefan Offermanns +13 more
TL;DR: In this article, the authors show that LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension, and that it is not sufficient to activate the signal in the smooth muscle alone.
Journal ArticleDOI
61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Mauricio Burotto,Zanete Zvirbule,A. Mochalova,Y. Runglodvatana,L.A. Herraez Baranda,S. Liu,Philip C.H. Chan,E. Shearer-Kang,M. R. Shivhare,Nadia Tosti,James Zanghi,Barbara Leutgeb,Enriqueta Felip +12 more
TL;DR: Atezo (anti-PD-L1) IV is approved in NSCLC, SCLC and triple-negative breast cancer, hepatocellular carcinoma, urothelial carcinoma and unresectable/metastatic melanoma as discussed by the authors .
Journal ArticleDOI
IMscin001 Part 2: A randomised phase III, open-label, multicentre study examining the pharmacokinetics (PK), efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous in previously treated locally advanced or metastatic non-small-cell lung cancer and PK comparison to other
Mauricio Burotto,Zanete Zvirbule,A. Mochalova,Y. Runglodvatana,Luis A. Herráez-Baranda,P J Chan,E. Shearer-Kang,X. Liu,Nadia Tosti,James Zanghi,Barbara Leutgeb,Enriqueta Felip +11 more
TL;DR: In this article , the authors compared the drug exposure of subcutaneous atezolizumab SC with IV, and found that SC provided non-inferior drug exposure at cycle 1 compared with IV.